TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia
EDINBURGH, Scotland, Nov. 27, 2023. TC BioPharm (Holdings) PLC ( " TC BioPharm " or the " Company " ) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, announced today that the FDA...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Leukemia | Pharmaceuticals | Scotland Health